These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 8819536

  • 1. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
    Foissier L, Lonchampt M, Cogé F, Canet E.
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536
    [Abstract] [Full Text] [Related]

  • 2. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM, Barnes PJ, Meja K, Giembycz MA.
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [Abstract] [Full Text] [Related]

  • 3. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, Taylor JD, Furdon PJ.
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [Abstract] [Full Text] [Related]

  • 4. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM, Xie QM, Tang HF, Sun JG, Deng JF, Chen JQ, Yang SY.
    Eur J Pharmacol; 2006 Oct 10; 547(1-3):125-35. PubMed ID: 16956605
    [Abstract] [Full Text] [Related]

  • 5. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN, Shiloh AO, Sauermelch CF, Sulpizio A, Michell MP, Cieslinski LB, Torphy TJ, Ohlstein EH.
    J Cereb Blood Flow Metab; 1997 Feb 10; 17(2):210-9. PubMed ID: 9040501
    [Abstract] [Full Text] [Related]

  • 6. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
    Cheng JB, Watson JW, Pazoles CJ, Eskra JD, Griffiths RJ, Cohan VL, Turner CR, Showell HJ, Pettipher ER.
    J Pharmacol Exp Ther; 1997 Feb 10; 280(2):621-6. PubMed ID: 9023272
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators.
    Derian CK, Santulli RJ, Rao PE, Solomon HF, Barrett JA.
    J Immunol; 1995 Jan 01; 154(1):308-17. PubMed ID: 7995950
    [Abstract] [Full Text] [Related]

  • 8. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P, Prigent AF, Lagarde M, Nemoz G.
    Mol Pharmacol; 1993 Nov 01; 44(5):1027-35. PubMed ID: 8246905
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma.
    Sun JG, Deng YM, Wu X, Tang HF, Deng JF, Chen JQ, Yang SY, Xie QM.
    Life Sci; 2006 Oct 26; 79(22):2077-85. PubMed ID: 16875702
    [Abstract] [Full Text] [Related]

  • 10. Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE, Houghton C, Sardar N, Withnall MT.
    Br J Pharmacol; 1997 Jun 26; 121(4):743-50. PubMed ID: 9208143
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM, Barnes PJ, Giembycz MA.
    Cell Biochem Biophys; 1998 Jun 26; 29(1-2):179-201. PubMed ID: 9631245
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E, Lee R, Near R, Weintraub L, Wolda S, Lerner A.
    Clin Cancer Res; 2002 Feb 26; 8(2):589-95. PubMed ID: 11839681
    [Abstract] [Full Text] [Related]

  • 13. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
    Gantner F, Götz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A.
    Br J Pharmacol; 1998 Mar 26; 123(6):1031-8. PubMed ID: 9559883
    [Abstract] [Full Text] [Related]

  • 14. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors.
    Tsafriri A, Chun SY, Zhang R, Hsueh AJ, Conti M.
    Dev Biol; 1996 Sep 15; 178(2):393-402. PubMed ID: 8812137
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of cAMP-specific PDE-4 activity following ligation of the TCR complex on thymocytes is blocked by selective inhibitors of protein kinase C and tyrosyl kinases.
    Michie AM, Rena G, Harnett MM, Houslay MD.
    Cell Biochem Biophys; 1998 Sep 15; 28(2-3):161-85. PubMed ID: 9515165
    [Abstract] [Full Text] [Related]

  • 16. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
    Essayan DM, Kagey-Sobotka A, Lichtenstein LM, Huang SK.
    J Pharmacol Exp Ther; 1997 Jul 15; 282(1):505-12. PubMed ID: 9223593
    [Abstract] [Full Text] [Related]

  • 17. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A.
    Br J Pharmacol; 1997 May 15; 121(2):221-31. PubMed ID: 9154331
    [Abstract] [Full Text] [Related]

  • 18. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
    Essayan DM, Huang SK, Undem BJ, Kagey-Sobotka A, Lichtenstein LM.
    J Immunol; 1994 Oct 15; 153(8):3408-16. PubMed ID: 7930566
    [Abstract] [Full Text] [Related]

  • 19. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
    Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, Huang Z, Nicholson DW, Mancini JA.
    J Pharmacol Exp Ther; 2004 Aug 15; 310(2):752-60. PubMed ID: 15082748
    [Abstract] [Full Text] [Related]

  • 20. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K, Burke-Gaffney A, Hellewell PG.
    Br J Pharmacol; 1998 May 15; 124(1):229-37. PubMed ID: 9630364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.